Still, the MATCH basket trial is looking to enroll patients with both solid and liquid malignancies, including multiple myeloma, harboring NTRK1, NTRK2, or NTRK3 gene fusions into the larotrectinib subprotocol (NCT02465060). The gene discussed is NTRK3; the disease is plasma cell myeloma.